Top in allergy/asthma: Food allergy treatment; new practice parameters
Click Here to Manage Email Alerts
The FDA has granted priority review to omalizumab as a treatment for food allergy after accidental exposure, according to a press release.
If approved, omalizumab (Xolair; Genentech, Novartis) would be the first medicine to reduce reactions to multiple foods. It was the top story in allergy/asthma last week.
The second top story was about new anaphylaxis and atopic dermatitis treatment parameters that were developed by a joint task force comprising of members from the American College of Allergy, Asthma & Immunology and the American Academy of Allergy, Asthma & Immunology.
Read these and more top stories in allergy/asthma below:
FDA grants priority review to omalizumab in treatment of food allergy
The FDA has accepted a supplemental biologics application for the use of omalizumab to reduce allergic reactions due to accidental exposure in patients aged 1 year and older with at least one food allergy, according to a press release. Read more.
Joint task force releases anaphylaxis, atopic dermatitis treatment parameters
Two new practice parameters from a joint task force published in Annals of Allergy, Asthma & Immunology provide evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis. Read more.
Q&A: Peanut bullying incident reveals opportunities for food allergy education, engagement
Two football players at Lake Travis High School in Lake Travis, Texas, have been accused of coating the cleats and uniform of a teammate with a severe peanut allergy in peanut products. The teammate developed hives. Read more.
Garadacimab application accepted for FDA review in hereditary angioedema treatment
The FDA has accepted a biologics license application for garadacimab as a monthly prophylactic treatment for hereditary angioedema, according to a press release from the manufacturer. Read more.
Asthma mortality rates higher in China than in the US, but the gap is closing
China had a higher asthma mortality rate than the United States between 1990 and 2019, driven by smoking, high BMI and age, but this gap narrowed with time, according to a study published in the Chinese Medical Journal. Read more.